US 12,239,636 B2
Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia
Philippe Marambaud, Astoria, NY (US)
Assigned to THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, Manhasset, NY (US)
Appl. No. 17/274,725
Filed by THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, Manhasset, NY (US)
PCT Filed Sep. 24, 2019, PCT No. PCT/US2019/052551
§ 371(c)(1), (2) Date Mar. 9, 2021,
PCT Pub. No. WO2020/068719, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/736,564, filed on Sep. 26, 2018.
Prior Publication US 2021/0346355 A1, Nov. 11, 2021
Int. Cl. A61K 31/436 (2006.01); A61K 31/496 (2006.01); A61P 7/04 (2006.01); A61P 7/06 (2006.01)
CPC A61K 31/436 (2013.01) [A61K 31/496 (2013.01); A61P 7/04 (2018.01); A61P 7/06 (2018.01)] 24 Claims
 
1. A method of treating one or more of an arteriovenous malformation, a vascular lesion and bleeding in a subject who has hereditary hemorrhagic telangiectasia (HHT) comprising administering to the subject sirolimus and nintedanib in therapeutically effective amounts to treat an arteriovenous malformation, a vascular lesion and/or bleeding in the subject, wherein sirolimus and nintedanib are the only therapeutic agents administered to the subject.